Current stock page

Financial Data

BIO Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareMedical - DevicesScore data as of Nov 18, 2026

BIOBio-Rad Laboratories, Inc.

Healthcare / Medical - Devices

Leader

Sector Leader

BullishEdge 10/10
$370.17+$11.98 (+3.34%)

Latest quote

  • Momentum
    79
  • Value
    80
  • Quality
    61
  • Risk resilience
    74
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

Latest Quarter at a Glance

Quarter ended Sep 30, 2026, compared with the same quarter a year earlier.

Revenue
$656.4M
+0.5% YoY
Net income
$458.6M
+234.1% YoY
Free cash flow
$65.2M
−26.9% YoY
Operating margin
-7.6%
−17.7 pts YoY

Quarterly Financial Statements

Updated Nov 19, 2026.

BIO, last 8 quarters. YoY compares the latest quarter with the same quarter a year earlier.

Income statement
Income statement, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Revenue+0.5%$656M$651M$592M$693M$653M$652M$585M$667M
Gross profit−4.3%$329M$346M$309M$345M$343M$345M$306M$342M
Operating income−174.8%−$50M$73M$34M$62M$66M$77M$24M$58M
Net income+234.1%$459M$371M−$527M$720M−$342M$318M$64M−$716M
EPS (diluted)+234.0%$17.02$13.85−$19.55$26.65−$12.70$11.67$2.29−$25.57
Gross margin−2.5 pts50.1%53.1%52.3%49.8%52.6%53.0%52.3%51.2%
Operating margin−17.7 pts-7.6%11.2%5.8%8.9%10.2%11.8%4.0%8.7%
Net margin+122.2 pts69.9%57.1%-89.0%103.9%-52.4%48.8%10.9%-107.2%
Cash flow
Cash flow, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Operating cash flow−20.3%$96M$99M$108M$165M$121M$117M$130M$124M
Capital expenditure+1.6%−$31M−$32M−$30M−$46M−$32M−$46M−$34M−$43M
Free cash flow−26.9%$65M$67M$78M$119M$89M$71M$96M$81M
Free cash flow margin−3.7 pts9.9%10.2%13.2%17.2%13.7%10.9%16.3%12.2%
Balance sheet
Balance sheet, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Total assets+11.2%$10.78B$10.25B$9.79B$10.58B$9.70B$10.21B$9.53B$9.36B
Total liabilities+7.5%$3.18B$3.08B$2.94B$3.12B$2.96B$3.09B$2.85B$2.79B
Shareholders' equity+12.9%$7.60B$7.17B$6.85B$7.45B$6.74B$7.13B$6.68B$6.57B
Total debt−2.3%$1.36B$1.20B$1.38B$1.53B$1.40B$1.41B$1.37B$1.37B
Cash and equivalents+17.0%$465M$517M$507M$532M$398M$369M$521M$488M
Valuation and ratios
Valuation and ratios, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
P/E ratio9.7240.1344.7410.39—20.64——
P/B ratio+0.031.311.241.101.061.280.921.011.18
Return on equity+23.5 pts13.5%3.1%2.5%10.2%-10.0%4.5%-32.4%-28.1%
Debt to equity−0.030.180.170.200.210.210.200.210.21
Free cash flow yield−0.6 pts3.3%4.0%4.7%4.7%3.9%5.3%4.9%3.4%

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
P/E ratio9.39x
P/B ratio1.26x
Revenue growth (YoY)0.52%
EPS growth (YoY)234.88%
Gross margin51.26%
Operating margin4.59%
ROE14.07%
ROIC0.90%
Debt to equity0.18
FCF yield3.42%

As of Nov 18, 2026

Technical indicators
MetricValue
Close
As of Nov 18, 2026
$370.17
Volume
As of Nov 13, 2026
256,211
RSI (14)
As of Nov 13, 2026
45.43
MACD
As of Nov 13, 2026
2.06
MACD signal
As of Nov 13, 2026
2.49
MACD histogram
As of Nov 13, 2026
-0.43
ADX (14)
As of Nov 13, 2026
12.87
SMA (50)
As of Nov 13, 2026
$372.95
SMA (200)
As of Nov 13, 2026
$316.99
ATR (14)
As of Nov 13, 2026
$13.05
Historical volatility (annualized)
As of Nov 13, 2026
31.37%
Volume (20-day average)
As of Nov 13, 2026
256,330
Risk measures
MetricValue
Resilience score74/100
Beta0.73
Annual volatility36.18%
Max drawdown-27.24%
Sharpe ratio0.47
VaR (95%, 1-day)-2.97%

As of Nov 18, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

BIO Financial Data FAQ

What is Bio-Rad Laboratories, Inc.'s revenue?

Bio-Rad Laboratories, Inc.'s revenue is one of the core financial data points for BIO. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Bio-Rad Laboratories, Inc.'s revenue growing?

Revenue growth shows whether Bio-Rad Laboratories, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is BIO's EPS?

BIO's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Bio-Rad Laboratories, Inc.'s net income?

Bio-Rad Laboratories, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Bio-Rad Laboratories, Inc. generate?

Free cash flow shows how much cash Bio-Rad Laboratories, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Bio-Rad Laboratories, Inc. have?

Cash and debt help frame BIO's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.